Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,178,410 shares, a growth of 32.3% from the February 15th total of 1,647,042 shares. Based on an average daily trading volume, of 552,604 shares, the days-to-cover ratio is presently 3.9 days. Approximately 4.6% of the company’s stock are short sold.

Several research analysts have recently weighed in on the stock. HC Wainwright set a $12.00 price target on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 4th. Bank of America assumed coverage on shares of Foamix Pharmaceuticals in a report on Wednesday, December 12th. They issued a “buy” rating and a $11.00 price target for the company. Finally, Cowen set a $30.00 price target on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $14.69.

In related news, insider Matthew T. Wiley purchased 13,440 shares of Foamix Pharmaceuticals stock in a transaction dated Tuesday, March 5th. The stock was bought at an average price of $3.76 per share, for a total transaction of $50,534.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.30% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in FOMX. Wells Fargo & Company MN boosted its holdings in Foamix Pharmaceuticals by 31.7% during the third quarter. Wells Fargo & Company MN now owns 132,900 shares of the specialty pharmaceutical company’s stock worth $761,000 after purchasing an additional 32,013 shares during the last quarter. AXA boosted its holdings in Foamix Pharmaceuticals by 43.8% during the third quarter. AXA now owns 1,369,341 shares of the specialty pharmaceutical company’s stock worth $7,846,000 after purchasing an additional 416,787 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Foamix Pharmaceuticals by 26.9% during the third quarter. Bank of New York Mellon Corp now owns 636,127 shares of the specialty pharmaceutical company’s stock worth $3,645,000 after purchasing an additional 134,676 shares during the last quarter. Trexquant Investment LP boosted its holdings in Foamix Pharmaceuticals by 205.6% during the third quarter. Trexquant Investment LP now owns 34,950 shares of the specialty pharmaceutical company’s stock worth $200,000 after purchasing an additional 23,515 shares during the last quarter. Finally, Credit Suisse AG acquired a new position in Foamix Pharmaceuticals during the third quarter worth $194,000. Institutional investors and hedge funds own 60.60% of the company’s stock.

Shares of FOMX opened at $4.03 on Friday. Foamix Pharmaceuticals has a 12 month low of $3.21 and a 12 month high of $7.60. The firm has a market cap of $222.92 million, a P/E ratio of -2.37 and a beta of 1.68.

COPYRIGHT VIOLATION NOTICE: “Foamix Pharmaceuticals Ltd (FOMX) Short Interest Up 32.3% in February” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2019/03/15/foamix-pharmaceuticals-ltd-fomx-short-interest-up-32-3-in-february.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

See Also: What is a Market Correction?

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.